FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316776483> ?p ?o ?g. }

• W2316776483 endingPage "96" @default.
• W2316776483 startingPage "88" @default.
• W2316776483 abstract "A novel series of 2-(3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)-N-(4-substitutedbenzylidene)acetohydrazide (12a-g) was prepared and their structures were confirmed by spectral and elemental analyses. The cytotoxic activity of the newly synthesized compounds was evaluated against breast carcinoma (MCF-7), non-small cell lung cancer (A549) and human colorectal adenocarcinoma (HT-29) cell lines using MTT and colony formation assays. The tested compounds showed a marked anticancer activity against all the tested cell lines, especially compound 12g, which was the most potent anticancer agent with half maximal inhibitory concentrations (IC50) between 5.36 and 9.09μM. Docking studies into ATP binding site of EGFR protein tyrosine kinase were performed to predict their scores and mode of binding to amino acids, In addition, the inhibitory activity of the target compounds against epidermal growth factor receptor tyrosine kinase (EGFR-TK) was evaluated. Results indicated the ability of the target compounds to inhibit EGFR-TK with half maximal inhibitory concentrations (IC50) in the range of 4.18-35.88μM. Furthermore, The most active compounds 12g, 12c and 12d were assayed against Fibroblast Growth Factor Receptor (FGFR), Insulin Receptor (IR) and Vascular Endothelial Growth Factor Receptor (VEGFR). The activity of the reported compounds warrants further optimization as novel members in cancer treatment protocols." @default.
• W2316776483 created "2016-06-24" @default.
• W2316776483 creator A5001687040 @default.
• W2316776483 creator A5010273416 @default.
• W2316776483 creator A5043581345 @default.
• W2316776483 creator A5081083092 @default.
• W2316776483 date "2016-06-01" @default.
• W2316776483 modified "2023-10-01" @default.
• W2316776483 title "Design, synthesis and antitumor activity of novel pyrazolo[3,4-d]pyrimidine derivatives as EGFR-TK inhibitors" @default.
• W2316776483 cites W1983790923 @default.
• W2316776483 cites W1988813296 @default.
• W2316776483 cites W2000785729 @default.
• W2316776483 cites W2003513576 @default.
• W2316776483 cites W2013759118 @default.
• W2316776483 cites W2028459193 @default.
• W2316776483 cites W2039879244 @default.
• W2316776483 cites W2046847279 @default.
• W2316776483 cites W2070587730 @default.
• W2316776483 cites W2070822454 @default.
• W2316776483 cites W2070930271 @default.
• W2316776483 cites W2077384736 @default.
• W2316776483 cites W2078690271 @default.
• W2316776483 cites W2089647609 @default.
• W2316776483 cites W2097814529 @default.
• W2316776483 cites W2101630681 @default.
• W2316776483 cites W2103625523 @default.
• W2316776483 cites W2105662969 @default.
• W2316776483 cites W2133051701 @default.
• W2316776483 cites W2143278515 @default.
• W2316776483 cites W2147811178 @default.
• W2316776483 cites W2154583637 @default.
• W2316776483 cites W2156972915 @default.
• W2316776483 cites W2157704894 @default.
• W2316776483 cites W2165571648 @default.
• W2316776483 cites W2174463797 @default.
• W2316776483 cites W2175404475 @default.
• W2316776483 cites W2316189352 @default.
• W2316776483 cites W2949871577 @default.
• W2316776483 doi "https://doi.org/10.1016/j.bioorg.2016.03.011" @default.
• W2316776483 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27043178" @default.
• W2316776483 hasPublicationYear "2016" @default.
• W2316776483 type Work @default.
• W2316776483 sameAs 2316776483 @default.
• W2316776483 citedByCount "57" @default.
• W2316776483 countsByYear W23167764832016 @default.
• W2316776483 countsByYear W23167764832017 @default.
• W2316776483 countsByYear W23167764832018 @default.
• W2316776483 countsByYear W23167764832019 @default.
• W2316776483 countsByYear W23167764832020 @default.
• W2316776483 countsByYear W23167764832021 @default.
• W2316776483 countsByYear W23167764832022 @default.
• W2316776483 countsByYear W23167764832023 @default.
• W2316776483 crossrefType "journal-article" @default.
• W2316776483 hasAuthorship W2316776483A5001687040 @default.
• W2316776483 hasAuthorship W2316776483A5010273416 @default.
• W2316776483 hasAuthorship W2316776483A5043581345 @default.
• W2316776483 hasAuthorship W2316776483A5081083092 @default.
• W2316776483 hasConcept C101544691 @default.
• W2316776483 hasConcept C146285616 @default.
• W2316776483 hasConcept C14858245 @default.
• W2316776483 hasConcept C159110408 @default.
• W2316776483 hasConcept C167734588 @default.
• W2316776483 hasConcept C170493617 @default.
• W2316776483 hasConcept C185592680 @default.
• W2316776483 hasConcept C202751555 @default.
• W2316776483 hasConcept C2777025900 @default.
• W2316776483 hasConcept C2777506169 @default.
• W2316776483 hasConcept C2777752497 @default.
• W2316776483 hasConcept C2779438470 @default.
• W2316776483 hasConcept C2780580887 @default.
• W2316776483 hasConcept C2780783641 @default.
• W2316776483 hasConcept C41685203 @default.
• W2316776483 hasConcept C42362537 @default.
• W2316776483 hasConcept C502942594 @default.
• W2316776483 hasConcept C54355233 @default.
• W2316776483 hasConcept C55493867 @default.
• W2316776483 hasConcept C62112901 @default.
• W2316776483 hasConcept C71924100 @default.
• W2316776483 hasConcept C81885089 @default.
• W2316776483 hasConcept C86803240 @default.
• W2316776483 hasConcept C98274493 @default.
• W2316776483 hasConceptScore W2316776483C101544691 @default.
• W2316776483 hasConceptScore W2316776483C146285616 @default.
• W2316776483 hasConceptScore W2316776483C14858245 @default.
• W2316776483 hasConceptScore W2316776483C159110408 @default.
• W2316776483 hasConceptScore W2316776483C167734588 @default.
• W2316776483 hasConceptScore W2316776483C170493617 @default.
• W2316776483 hasConceptScore W2316776483C185592680 @default.
• W2316776483 hasConceptScore W2316776483C202751555 @default.
• W2316776483 hasConceptScore W2316776483C2777025900 @default.
• W2316776483 hasConceptScore W2316776483C2777506169 @default.
• W2316776483 hasConceptScore W2316776483C2777752497 @default.
• W2316776483 hasConceptScore W2316776483C2779438470 @default.
• W2316776483 hasConceptScore W2316776483C2780580887 @default.
• W2316776483 hasConceptScore W2316776483C2780783641 @default.
• W2316776483 hasConceptScore W2316776483C41685203 @default.
• W2316776483 hasConceptScore W2316776483C42362537 @default.
• W2316776483 hasConceptScore W2316776483C502942594 @default.

• next